Cancer Diagnostics Market-Rising Prevalence of Cancer & Demand for New Diagnostic Techniques Accelerate the Growth of the Market

Cancer Diagnostics: Increasing Prevalence of Cancer is Expected to Boost The Market Growth During The Forecast Period 2025-2035

Market Research Future (MRFR) has published a cooked research report on the “Global Cancer Diagnostics Market” that contains information from 2019 to 2035. The Cancer Diagnostics Market is estimated to register a CAGR of 6.7% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Cancer Diagnostics Market — F. Hoffmann-La Roche Ltd (CH), Abbott Laboratories (US), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Illumina (US), Bristol-Myers Squibb (US), Agilent Technologies (US), Qiagen (NL), and Hologic (US).

Market Highlights

The Global Cancer Diagnostics Market is accounted for to register a CAGR of 6.7% during the forecast period and is estimated to reach 386.19 USD Billion by 2035, up from 189.19 USD Billion in 2024.

The market is driven by the increasing prevalence of cancer, rising awareness about early detection, and rapid advancements in diagnostic technologies such as next-generation sequencing (NGS), liquid biopsy, and AI-integrated imaging systems. These innovations enable faster, more accurate, and minimally invasive cancer detection, leading to improved patient outcomes and survival rates.

Growing investment in healthcare infrastructure, government-led cancer screening programs, and the adoption of precision medicine further strengthen market growth. The integration of AI in diagnostics is enhancing image analysis, enabling real-time insights and reducing human error in early-stage cancer identification.

Segment Analysis

The Global Cancer Diagnostics Market has been segmented based on Test Type, Cancer Type, End User, and Sample Type.

• By Test Type: Biopsy, Imaging, Blood Tests, and Molecular Testing. Among these, Imaging remains the dominant segment due to its accuracy and non-invasive nature, while Molecular Testing and Liquid Biopsy are emerging as fast-growing segments for their genetic precision.


• By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, and Colorectal Cancer. The Breast Cancer segment leads the market, supported by awareness programs and high screening adoption, followed by Lung Cancer due to the rising global incidence.


• By End User: Hospitals, Diagnostic Laboratories, and Research Institutes. Hospitals and diagnostic labs dominate due to advanced diagnostic infrastructure and accessibility.


• By Sample Type: Tissue, Blood, and Urine. The Blood sample segment is witnessing significant growth owing to the popularity of non-invasive liquid biopsies.

Regional Analysis

By Region, the Cancer Diagnostics Market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

• North America leads the global market, valued at 6.5 USD Billion in 2024, expected to reach 9.5 USD Billion by 2035, driven by advanced healthcare systems and strong R&D investments.


• Europe follows with a rise from 4.0 USD Billion in 2024 to 5.5 USD Billion by 2035, supported by favorable healthcare policies and public awareness campaigns.


• Asia Pacific is projected to be the fastest-growing market, increasing from 3.0 USD Billion in 2024 to 5.0 USD Billion by 2035, owing to a growing patient pool, expanding healthcare access, and rising disposable income.


• South America and the Middle East & Africa show steady growth with improving healthcare infrastructure and awareness.

Key Findings of the Study

• The Global Cancer Diagnostics Market is expected to reach 386.19 USD Billion by 2035, at a CAGR of 6.7% during the forecast period.


• Asia Pacific is projected to be the fastest-growing regional market.


• Based on Test Type, the Imaging segment accounted for the largest market share in 2024.


• Based on Cancer Type, Breast Cancer held the largest share in 2024.


• Roche, Thermo Fisher Scientific, Siemens Healthineers, Illumina, and Abbott Laboratories** are among the leading market players.

Future Outlook

The Cancer Diagnostics Market is set to experience strong growth through 2035, propelled by technological innovations, AI-enabled diagnostic systems, and expanding telemedicine-based screening. Emerging opportunities include:

• Development of AI-powered early detection tools.


• Integration of personalized medicine for genetic diagnostics.


• Expansion of remote and at-home testing solutions in emerging economies.

Related Reports

https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-2035